We solve the problem of fibrosis in soft-tissue repair.
Tens of millions people live today with one or more surgical implant. Every time a patient receives a surgical implant, the body recognizes the artificial material as foreign and classifies it as dangerous. In response to this, the implant is finally covered by a thick layer of fibrotic tissue, which hardens and contracts over time in the attempt of isolating, killing and expelling the foreign body.
Fibrosis is leading cause of
- Patient's Pain
- Implant Failure
- Impaired Quality of Life
There is currently no solution to implants' fibrosis except for Revision Surgery (the removal of the old implant and implantation of a new one). This procedure levitates the Healthcare Costs.
The Anti-Fibrotic Surgical Pouch
The cellulose film that fully prevents fibrosis.
The Underlying Science
We developed a technology to produce cellulose films that fully prevent fibrosis.
These films are easy-to-handle by the surgeons and ergonomically fit the target implant. The surgeons can mount them on the implants prior to surgery, without affecting the rest of the procedure.
The uniqueness of our patented technology consists in micro-engineering cellulose in a novel biotech process with a rationally designed surface architecture. This ultimately endows the cellulose layer with anti-fibrotic properties. Similar to Braille reading, when getting in touch with the cellulose interface, the hosting tissue is instructed to avoid fibrosis and to shut down the foreign body reaction.
A platform technology that applies to all sorts of soft tissue repair which may be impaired by foreign body reaction and fibrosis. The potential applications include:
Reconstructive & Plastic Surgery
- Ventriculo Peritoneal Shunts
- VentricularAssist Devices
- Pacemakers etc.
- Hernia Meshes
- Tendon Repair
Platform technology for soft-tissue repair
- Implantable Pumps (diabetes and chronic pain management)
- Bionic Limbs
- Intraocular Lenses
- Glaucoma Drainage Devices
- Laparoscopic Bands
- Surgical Barriers
Today's top-class state-of-the-art implants need revision in more than 10-20% reconstructive (post-cancer mastectomy) AND aesthetic patients, respectively. There is an additional 25% chance that revised patients will experience multiple revisions. We estimate that healthcare costs in relation with these unnecessary revision surgeries exceed 1 billion USD/year in US alone.
Thanks to HYLOCARE TM there will be no revision surgery due to fibrosis. Patients will experience no pain, and healthcare systems will not bear the related costs.
Are you interested? Do you want to know about the status of our development and regulatory approval process? Do you wish to use our technology in your daily work?
Who are we?
HYLOMORPH AG is an innovative spin-off of the Swiss Federal Institute of Technology (ETH Zurich) specialized in biomaterials and their interfacing with human tissues.
We originated in and are currently based at the Department of Mechanical and Process Engineering of ETH Zurich. We collaborate with the University Hospital Zurich and the Deutsches Herzzentrum Berlin for our clinical development.
Sonneggstrasse3, ML J 27.1
8092, Zurich Switzerland
+41 44 632 78 58
The information contained in this website is for general information purposes only. Links taken to other websites are done soatvisitors' own risk and HYLOMORPH AG accepts no liability for any linked sites or their content.
Oct 2016: Our clinical advisor presents preliminary results at the annual congress of the International Society of Aesthetic and Plastic Surgery Read more»
Sep 2016: We finalise our first round of pre-clinical investigation!! Usability testing was successful and great results are about to be published...
Aug 2016: HYLOMORPH pitches at BioInterfaces 2016 Read more»
Jul 2016: HYLOMORPH is incubated at the Wyss Translational Center Zurich Read more»
Feb 2016: HYLOMORPH AG is awarded with the Venturekick-Stage III Read more»
May 2015: HYLOMORPH AG is awarded with the Venturekick-Stage II Read more»
Mar 2015: HYLOMORPH AG is awarded the VentureLeaders 2015 and will participate in the "Swiss National Startup Team" traveling to Boston, New York and Philadelphia in June. Read more»
Jan 2015: HYLOMORPH AG is awarded with the Venturekick-Stage I. Read more»
Nov 2014: HYLOMORPH AG is incorporated with headquarters in Zurich
Mar 2014: HYLOMORPH nominated Top 5 patents in the Spark Award 2014. Read more»
May 2013: the HYLOMORPH project is awarded with the Pioneer Fellowship
- 30.1.2017 Unique membrane optimises interface between implants and human tissue (German)
- 17.2.2016 Kick-start your startup
- 27.3.2015 Swiss startups ready to take over the World.
- 19.1.2015 Cellulose with Braille for Cells.
- 19.12.2014 Bottan S, Robotti F, Jayathissa P, Hegglin A, Bahamonde N, Heredia-Guerrero JA, Bayer IS, Scarpellini A, Merker H, Lindenblatt N, Poulikakos D, Ferrari A: Surface-Structured Bacterial Cellulose with Guided Assembly-Based Biolithography (GAB). ACS Nano, online publication, 19 December 2014, doi:10.1021/nn5036125
Interested? Currently there are no positions that fits your profile, but you are still interested in joining our team? We are always ready to consider motivated applicants. Submit your spontaneous application: surprise us with your CV and motivation letter here.